{
  "id": 16290495,
  "title": "Immunovant CTO Jay Stout sells $75,099 in shares",
  "url": "https://urgent.news/2026/10/24/immunovant-cto-jay-stout-sells-75-099-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-24T06:01:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/immunovant-cto-jay-stout-sells-75099-in-shares-93CH-4970640"
  },
  "original_language": "en",
  "account": "Immunovant CTO Jay Stout transferred 2,595 shares of the company's stock on October 21, 2026. The sale occurred to satisfy tax withholding requirements for restricted stock units (RSUs) granted on April 17, 2023, with 6,250 shares vesting on October 17, 2026. The sale, totaling $75,099, took place at an average price of $28.94 per share, between $28.31 and $29.15 per share. This sale does not indicate a discretionary decision by Stout, but rather reflects Immunovant's policy to fund tax withholding obligations. Stout now directly owns 198,937 shares of Immunovant common stock, following the transaction. Immunovant, valued at $6 billion, currently has more cash than debt on its balance sheet, according to InvestingPro analysis, though the stock is deemed overvalued relative to its Fair Value.",
  "summary": null,
  "key_points": [
    "Immunovant CTO Jay Stout sold 2,595 shares on October 21, 2026",
    "Sale of $75,099 to meet tax withholding for RSUs",
    "Stout retains 198,937 shares after transaction"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}